Previous 10 | Next 10 |
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelin Preclinical programs targeting PRAME and CD70 in IND-enabling studies Adaptimmune funded ...
Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1 trial and the median duration of response was ~12 months (CTOS 2022) Median overall survival (mOS) was ~17 months Patients with a RECIST response have a 12-month OS prob...
2023-05-12 13:09:08 ET Adaptimmune Therapeutics plc (ADAP) Q1 2023 Earnings Conference Call May 12, 2023, 08:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, La...
2023-05-12 08:39:11 ET Adaptimmune press release ( NASDAQ: ADAP ): Q1 GAAP EPS of $0.00 beats by $0.14 . Revenue of $47.6M (+1222.2% Y/Y). For further details see: Adaptimmune GAAP EPS of $0.00 beats by $0.14, revenue of $47.6M
2023-05-11 12:11:35 ET Adaptimmune ( NASDAQ: ADAP ) is scheduled to announce Q1 earnings results on Friday, May 12th, before market open. The consensus EPS Estimate is -$0.17 and the consensus Revenue Estimate is $4.6M (+27.8% Y/Y). Over the last 1 year, ADAP has bea...
2023-05-11 11:47:13 ET Major earnings expected before the bell on Friday include: Air Canada ( OTCQX:ACDVF ) Allianz SE ( OTCPK:ALIZF ) Crescent Point Energy ( CPG ) Charlotte's Web Holdings ( OTCQX:CWBHF ) Tata Motors ( TTM ) For further deta...
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2023, before...
2023-04-21 14:24:33 ET Summary ADAP is swapping 1.5117 of its shares for every TCRR share. There is a huge spread between the two values, so existing shareholders can lock in a big gain once the deal closes. The spread is available as an arbitrage (by shorting ADAP) with a few...
2023-04-18 16:37:11 ET Adaptimmune Therapeutics ( NASDAQ: ADAP ) and TCR Therapeutics ( NASDAQ: TCRR ) have set May 30 for shareholder votes on their planned combination. The vote is scheduled for 7:30am EST at the Adaptimmune's ( ADAP ) headquarters in the UK, acc...
2023-04-11 12:13:33 ET Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the rights to Adaptimmune's PRAME and NY-ESO cell therapy...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...